Interpace Biosciences Eulerpool News

Interpace Biosciences Aktie News

Interpace Biosciences wird von vielen Journalisten und Investoren weltweit beobachtet. Die aktuellsten Interpace Biosciences News stellen wir hier zusammen.

• 24. April ·

  Yahoo
  Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
• 10. Januar ·

  Yahoo
  Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
• 4. November ·

  Yahoo
  Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
• 15. Oktober ·

  Yahoo
  Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
• 15. Oktober ·

  TipRanks
  Interpace Diagnostics Strategic Stock Exchange for Nasdaq Uplisting
• 2. August ·

  Seeking Alpha
  Interpace Biosciences GAAP EPS of $0.48, revenue of $12M
• 1. August ·

  Yahoo
  Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
• 29. Juli ·

  Yahoo
  Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
• 29. Juli ·

  Thefly.com
  Interpace Biosciences announces extension of Medicare coverage for PancraGEN